Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most active single agents for the treatment of non-small cell lung cancer, with response rates of 21% to 24%. We present a phase I study with paclitaxel and simultaneous radiation in previously untreated, locally advanced, inoperable, stage IIIA/B non-small cell lung cancer. The aims of the study were to determine the maximum tolerated dose, define the safety and toxicity, and obtain preliminary data about the activity of the combined modality. Patients received a fixed dose of radiotherapy (1.8 Gy/d, 5 days a week for 6.5 weeks, for a total dose of 59.4 Gy) and concomitant chemotherapy with paclitaxel 45 mg/m2 days 1, 8, and 15 in level 1; days 1, 8, 15, 22, and 29 in level 2; and days 1, 8, 15, 22, 29, 36, and 43 in level 3. The paclitaxel dosage was increased to 55 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43 in level 4. Paclitaxel was administered as a 3-hour continuous intravenous infusion. Dexamethasone, clemastine, and ranitidine were given for hypersensitivity prophylaxis. Twenty-two patients (18 men and four women) entered the study; their median age was 66.5 years (age range, 38 to 74 years). Disease stage was IIIA in six of 22 patients and stage IIIB in 16. Six patients were treated at level 1, five at level 2, five at level 3, and six at level 4. There were 18 patients evaluable for toxicity and response. Side effects generally were moderate during the treatment period. One patient withdrew by request after the first course, one patient died of tumor bleeding after five courses, one patient died of progressive disease (lymphangiosis carcinomatosa of both lungs) after the sixth course, and one patient is too early for evaluation. Among the 18 patients evaluable for response, there were one complete and 10 partial remissions; seven patients reached a minor response. It is concluded that the therapy was well tolerated in these patients. Importantly, no severe adverse events were observed that could be associated with paclitaxel or radiotherapy. This combined modality appears to be a practicable and effective treatment of non-small cell lung cancer. The maximum tolerated dose has not yet been reached, and dose escalation is planned.
Vogt
H G
HG
Department of Radiation Medicine, Städtische Kliniken Offenbach, Germany.
Kolotas
C
C
Martin
T
T
Schneider
L V
LV
Goes-Schmieder
R
R
Mitrou
P S
PS
Diergarten
K
K
Kober
B
B
Zamboglou
N
N
D000328:Adult; D000368:Aged; D018926:Anti-Allergic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000633:toxicity; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy / Q000628:therapy*; D002974:Clemastine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000517:prevention & control; D004361:Drug Tolerance; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000633:toxicity; D011292:Premedication; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000633:toxicity; D011879:Radiotherapy Dosage; D011899:Ranitidine / Q000008:administration & dosage; D012074:Remission Induction; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D000972:Antineoplastic Agents, Phytogenic; D006635:Histamine H2 Antagonists; D011838:Radiation-Sensitizing Agents; D003907:Dexamethasone; D011899:Ranitidine; D002974:Clemastine; D017239:Paclitaxel